Logo

Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies

Share this
Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies

Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies

Shots:

  • The companies collaborate to develop novel species-specific mAb biotherapeutics targeting a wide range of diseases in the veterinary species with an initial focus on dogs and cats
  • The collaboration will utilize Invetx’s discovery platform- optimization technologies- and Ab expertise to develop veterinary biotherapeutics against selected targets for chronic & serious diseases in animals
  • Boehringer Ingelheim will boost veterinary therapies through clinical and regulatory development to the commercialization of the products

  | Ref: Boehringer Ingelheim | Image: Franchise India

Click here to­ read the full press release 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions